Alvotech (NASDAQ:ALVO) reported positive findings from a pharmacokinetic trial evaluating AVT80, its experimental biosimilar to Entyvio, after the study successfully achieved all primary objectives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results